Goldstone Financial Group LLC Buys Shares of 4,545 Bristol-Myers Squibb (NYSE:BMY)

Goldstone Financial Group LLC purchased a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,545 shares of the biopharmaceutical company’s stock, valued at approximately $235,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cornerstone Wealth Management LLC raised its position in shares of Bristol-Myers Squibb by 6.6% in the 1st quarter. Cornerstone Wealth Management LLC now owns 15,392 shares of the biopharmaceutical company’s stock worth $835,000 after acquiring an additional 948 shares in the last quarter. First Trust Direct Indexing L.P. raised its holdings in Bristol-Myers Squibb by 52.1% in the first quarter. First Trust Direct Indexing L.P. now owns 22,320 shares of the biopharmaceutical company’s stock worth $1,210,000 after purchasing an additional 7,649 shares in the last quarter. Norden Group LLC lifted its position in shares of Bristol-Myers Squibb by 30.2% during the first quarter. Norden Group LLC now owns 13,846 shares of the biopharmaceutical company’s stock valued at $751,000 after buying an additional 3,213 shares during the last quarter. Diversify Advisory Services LLC purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $1,217,000. Finally, Sequoia Financial Advisors LLC grew its position in shares of Bristol-Myers Squibb by 54.8% in the 1st quarter. Sequoia Financial Advisors LLC now owns 119,293 shares of the biopharmaceutical company’s stock worth $6,469,000 after buying an additional 42,244 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Trading Up 5.8 %

Bristol-Myers Squibb stock opened at $55.74 on Friday. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. The firm has a market cap of $113.01 billion, a PE ratio of -17.10, a P/E/G ratio of 13.75 and a beta of 0.46. The stock’s 50 day simple moving average is $51.14 and its two-hundred day simple moving average is $46.54. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $56.20.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.31%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -73.62%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on BMY shares. Barclays raised their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. TD Cowen raised their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Finally, Jefferies Financial Group lifted their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research note on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $52.38.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.